TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Subject is a male or female aged 6-12 years inclusive at the time of consent.~2. Females of Child-bearing Potential (FOCP) must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to comply with any applicable contraceptive requirements of the protocol.~3. primary diagnosis of ADHD based on a detailed psychiatric evaluation.~4. Subjects must have a baseline ADHD-RS-IV total score ≥28.~5. Subject is functioning at an age-appropriate level intellectually.~6. comply with all the testing and requirements.~7. Subject is able to swallow a capsule.~8. Subject has blood pressure measurements within the 95th percentile for age, gender, and height.~Exclusion Criteria~1. Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder or other symptomatic manifestations.~2. Subject has Conduct Disorder.~3. Subject has a documented allergy, hypersensitivity, or intolerance to amphetamines.~4. Subject has failed to respond to one or more adequate courses (dose and duration) of amphetamine therapy.~5. The subject has a recent history (within the past 6 months) of suspected substance abuse or dependence.~6. Subject has a positive urine drug result.~7. Subject weighs less than 50 pounds (22.7kg).~8. Subject is significantly overweight.~9. Subject has a history of seizures (exclusive of febrile seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.~10. Subject has any reported history of abnormal thyroid function.~11. Subject has taken another investigational product or taken part in a clinical trial within 30 days prior to Screening.~12. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments.~13. The female subject is pregnant or lactating.~14. Subject is well-controlled on their current ADHD medication with acceptable tolerability.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) Class 1 or 2 physical status;~* 18 to 65 years of age (inclusive);~* Scheduled for elective surgical procedure under general anesthesia requiring a short duration of neuromuscular block with the use of rocuronium or succinylcholine and requiring endotracheal intubation;~* Scheduled for surgery in supine position;~* Body mass index (BMI) \< 30;~* Given written informed consent.~Exclusion Criteria:~* Has ischemic heart disease or history of myocardial infarction within the last year;~* May experience difficult intubation due to anatomical malformations;~* Known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction;~* Known or suspected family history of malignant hyperthermia;~* Known or suspected allergy to narcotics, muscle relaxants, midazolam, anesthetics or other medications used during surgery;~* Is receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and Mg2+;~* Individuals in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;~* Females who are pregnant or breast-feeding;~* Females of childbearing potential who are not using an acceptable method of birth control \[condom or diaphragm with spermicide, vasectomized partner (\> 6 months), IUD, abstinence\];~* Has already participated in a sugammadex trial including Protocol 19.4.303.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rocuronium + Sugammadex (Type: EXPERIMENTAL): Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
- Succinylcholine (Type: ACTIVE_COMPARATOR): Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subject chronically infected with HCV genotype 1 (GT-1)~* Subject without cirrhosis or with compensated cirrhosis (Child Pugh Class A)~* HCV RNA ≥ 10,000 IU/mL at screening~* Treatment-naïve subject with no previous exposure to an interferon formulation (ie, IFNα, pegIFNα), Ribavirin (RBV), or HCV DAA (protease, polymerase inhibitor, etc.)~* Interferon (IFN) experienced subject who have received previous treatment with IFNα, with or without RBV~Exclusion Criteria:~* Liver or any other transplant (including hematopoietic stem cell transplants) other than cornea and hair;~* Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening;~* Documented or suspected hepatocellular carcinoma (HCC), as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed);~* Evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 : DCV/ASV/BMS-791325 (Type: EXPERIMENTAL): DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any study assessment is performed~* Diagnosis of visual impairment exclusively due to ME secondary to BRVO~* BCVA score at Screening and Baseline between 73 and 19 letters (ETDRS)~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Stroke or myocardial infarction less than 3 months before Screening~* Uncontrolled blood pressure defined as systolic value of \>160 mm Hg or diastolic value of \>100 mm Hg at Screening or Baseline.~* Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye~* Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye~* Neovascularization of the iris or neovascular glaucoma in the study eye~* Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline~* Panretinal laser photocoagulation within 3 months before Baseline or anticipated or scheduled within the next 3 months following Baseline in the study eye~* Focal or grid laser photocoagulation within 4 months before Baseline in the study eye~* Use of intra- or periocular corticosteroids (including sub-Tenon) within 3 months before Screening in the study eye~* Any use of intraocular corticosteroid implants (eg, dexamethasone \[Ozurdex®\], fluocinolone acetonide \[Iluvien®\]) in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1-ranibizumab monotherapy (Type: EXPERIMENTAL): Ranibizumab 0.5 mg
- 2-ranibizumab with laser (Type: EXPERIMENTAL): Ranibizumab 0.5 mg + laser
- 3-laser monotherapy (Type: ACTIVE_COMPARATOR): Laser monotherapy with Ranibizumab 0.5 mg from Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* (STEP 1) - PRIMARY INTERVENTION STUDY (RANDOMIZED CONTROLLED TRIAL \[RCT\]):~* Patients must be registered to the first screening step (Step 0) for the National Cancer Institute (NCI)-MATCH trial (EAY131)~* Patients must speak English and have an adequate ability to view a website (primary intervention study)~* (STEP 2) - SECONDARY GENETIC COUNSELING SUBSTUDY:~* Patients must have a potential germline mutation, as determined by the NCI-MATCH tumor profiling assay~* Patients must be able to speak English and hear by phone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Step 1: internet-based intervention) (Type: EXPERIMENTAL): Patients receive web-based genetic education consisting of general information about testing tumors for genetic mutations.
- Arm B (Step 1: usual care control) (Type: ACTIVE_COMPARATOR): Patients receive standard genetic education consisting of conversations with the treating physicians, interaction with and information from the clinical staff, and information from usual resources about testing for genetic mutations.
- Step 2 - genetic counseling (Type: EXPERIMENTAL): Patients who meet the criteria for the remote counseling substudy will receive genetic counseling over the telephone and undergo germline testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Ticagrelor Versus Clopidogrel on Microcirculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* All patients with ACS scheduled for PCI will be eligible, assuming their ability to understand the character and individual consequences of participation as well as giving written informed consent.~* Be able to understand and comply with the requirements of the study, as judged by the investigator.~Exclusion Criteria:~* History of intracranial bleeding~* Severe hepatic impairment~* Active pathologic bleeding~* Hypersensitivity to ticagrelor or any of the excipients~* Liver cirrhosis greater than or equal to Child class B~* Decreased serum platelet level (≤ 100,000/uL)~* Life expectancy ≤ 1 year~* Need for chronic oral anticoagulant therapy~* Patients with known bleeding diathesis or coagulation disorder~* History of previous intracranial bleed at any time, gastrointestinal bleed within the past 6 months, or major surgery within 30 days.~* Ischemic stroke within the previous 14 days~* Renal failure requiring dialysis or anticipated need for dialysis during the course of the study~* Concern for inability of the patient to comply with study procedures and/or follow up~* Unable to give informed consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): Ticagrelor 90mg, twice a day
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 75mg, once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switch to Unboosted Atazanavir With Tenofovir Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV infected adults at least 19 years of age~2. Willing and able to provide informed consent to study participation~3. Currently receiving a regimen including atazanavir 300mg/ritonavir 100mg daily with either tenofovir/emtricitabine (FTC) or tenofovir/lamivudine (3TC), for at least 3 months~4. Plasma viral load (VL) \<40 copies/mL for at least 2 consecutive measurements including the screening value, and \< 150 copies/mL continuously for at least 3 months prior to screening~5. Current regimen is first antiretroviral regimen, or if not first regimen, no evidence of resistance to any nucleosides (NRTIs) or protease inhibitors (PIs) on previous resistance tests~6. Any CD4~Exclusion Criteria:~1. Clinically significant intolerance or toxicity with current regimen precluding regimen continuation (e.g. intolerance/toxicity to ritonavir necessitating ritonavir discontinuation)~2. pregnancy or breast-feeding~3. antiretroviral regimen including any nonnucleoside reverse transcriptase inhibitor (nevirapine, efavirenz, or etravirine)~4. antiretroviral regimen including any protease inhibitor other than atazanavir and ritonavir~5. concomitant treatment with proton pump inhibitors, rifampin, St. John's wort, or garlic supplements. (Antacids and H2 receptor antagonists will be allowed provided their dosing is separated from atazanavir administration by at least 2 and 10 hours, respectively).

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switch (Type: EXPERIMENTAL): switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
- Continuation (Type: ACTIVE_COMPARATOR): continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged ≥18 years~* able to provide informed consent~* had confirmed HIV infection~* on ART including atazanavir 300 mg and ritonavir 100 mg each day in the regimens that were not changed within 12 weeks before the randomization~* patients who had cholesterol level between 200 and 500 and LDL between 130 and 400 mg/dL without any lipid-lowering agent or discontinued the lipid-lowering agent at least 1 month prior to randomization~Exclusion Criteria:~* had the history of pitavastatin and/or the constituent of the drugs allergy~* known history of myocardial infarction and/or ischemic stroke within 1 month prior to the randomization that would be endangered if we stopped the previous lipid-lowering agent before the enrollment~* abnormal AST and ALT with level ≥5 times in asymptomatic patients or ≥3 times of upper normal limit (UNL) in symptomatic patients~* pregnancy or breastfeeding~* on cyclosporine which had major drug interactions with pitavastatin~* patients who denied to join the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment sequence A, B (Type: EXPERIMENTAL): Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
- Treatment sequence B, A (Type: EXPERIMENTAL): Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developing an Implementation Strategy for Post-concussion Communication With Low Health Literacy Parents in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Parent/guardian of a child between the ages of 5 and 17 who presented to the Seattle Children's Hospital Emergency Department and was treated for closed head injury.~* Child for whom care was sought was not admitted for inpatient care~* Parent/guardian of child without chronic disease or with non-complex chronic disease~* Parent/guardian with a preferred language for medical care of English or Spanish~* Parent/guardian present in the ED is child's legal guardian

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Education as usual (Type: NO_INTERVENTION): Participants receive education/healthcare provider communication as usual during their visit to the ED for concussion care.
- New education (Type: EXPERIMENTAL): Participants receive the newly developed educational intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to coronary ICU~* Admission blood glucose 140-299 mg/dL~* Primary cardiovascular diagnosis by attending physician~* Under primary care of cardiology service~* Age \> 18 years old~* Ventilator independent~* Able to provide informed consent~Exclusion Criteria:~* Admission blood glucose \< 140 or \> 300 mg/dL~* Ventilator dependent~* Unconscious sedation~* Type 1 diabetes~* Known pregnancy~* Admitted to coronary ICU for right heart cath to measure hemodynamics prior to transplant~* Post transplant procedure~* Currently enrolled in another clinical trial~* Unable to provide informed consent~* Creatinine clearance \< 30 mL/min~* On insulin treatment except for monotherapy with long-acting basal insulin (e.g., insulin glargine \[Lantus®\] or detemir \[Levemir®\])~* Gastroparesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): 0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opium Tincture Against Chronic Diarrhea - Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Signed informed consent before any study specific procedures~  * Able to read and understand Danish~ * Male or female with an age of 20 years or more~ * The researcher believes that the participant understands what the study entails, are capable of following instructions, can attend when needed, and are expected to complete the study.~ * The investigator will ensure that fertile female participants have a negative pregnancy test before each treatment visit and use contraception during the entity of the study.~ * Specific underlying pathophysiology has been identified, but targeted treatment (e.g. antibiotics or bile acid sequestrants) and treatment with loperamide has failed.~OR~* No specific underlying pathophysiology has been identified and treatment with loperamide has failed.~* At least 6 months post-surgery in the gastrointestinal tract~* No sign of cancer at standard clinical follow-up~* Chronic diarrhea defined as at least 3 daily bowel movements for the last week~Exclusion Criteria:~* • Known allergy towards pharmaceutical compounds similar to Dropizol.~  * Participation in other studies within 14 days of first visit (1 year if opioids involved).~ * Expected need of medical/surgical treatment during the study~ * History of psychiatric illness (e.g. mental retardation, schizophrenia, major depression)~ * History of substance abuse (e.g. alcohol, THC, benzodiazepine, central stimulants and/or opioids)~ * Family history of substance abuse~ * Known major stenosis of the intestines~ * Known severe decreased renal function (defined as eGFR below 30)~ * Known severe decreased hepatic function (defined as Child-Pugh class B or higher)~ * Treatment with MAO- inhibitors during the entity of the study~ * Severe COPD or acute severe asthma (defined as FEV1 below 50 % or acute ongoing exacerbation)~ * Known cor pulmonale~ * Female participants that are lactating~ * Medicine known to affect gastrointestinal motility must not be initiated during the entity of the study~ * Treatment with opium tincture during the last month

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: ACTIVE_COMPARATOR): Administration of opium tincture (Dropizol)
- Placebo treatment (Type: PLACEBO_COMPARATOR): Administration of placebo (identical to opium tincture in taste and appearance)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete